KRN-7000

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
KRN-7000
DrugBank Accession Number
DB12232
Background

KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 858.3224
Monoisotopic: 857.731983771
Chemical Formula
C50H99NO9
Synonyms
  • 1-O-(α-D-galactopyranosyl)-N-hexacosanoylphytosphingosine
External IDs
  • AGL-582
  • KRN 7000
  • KRN7000
  • RGI-2001

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-7000.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with KRN-7000.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with KRN-7000.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with KRN-7000.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glycosphingolipids. These are sphingolipids containing a saccharide moiety glycosidically attached to the sphingoid base. Although saccharide moieties are mostly O-glycosidically linked to the ceramide moiety, other sphingolipids with glycosidic bonds of other types (e.g. S-,C-, or N-type) has been reported.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Sphingolipids
Sub Class
Glycosphingolipids
Direct Parent
Glycosphingolipids
Alternative Parents
Fatty acyl glycosides of mono- and disaccharides / Alkyl glycosides / Hexoses / O-glycosyl compounds / N-acyl amines / Oxanes / Secondary alcohols / Secondary carboxylic acid amides / Polyols / Acetals
show 7 more
Substituents
Acetal / Alcohol / Aliphatic heteromonocyclic compound / Alkyl glycoside / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Fatty acyl / Fatty acyl glycoside / Fatty acyl glycoside of mono- or disaccharide
show 21 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
glycophytoceramide (CHEBI:466659)
Affected organisms
Not Available

Chemical Identifiers

UNII
WX671898JF
CAS number
158021-47-7
InChI Key
VQFKFAKEUMHBLV-BYSUZVQFSA-N
InChI
InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
IUPAC Name
N-[(2S,3S,4R)-3,4-dihydroxy-1-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadecan-2-yl]hexacosanamide
SMILES
CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC

References

General References
Not Available
PubChem Compound
2826713
PubChem Substance
347828511
ChemSpider
2104816
ChEBI
466659
ChEMBL
CHEMBL384200
ZINC
ZINC000087496076
PDBe Ligand
AGH
PDB Entries
1zt4 / 2po6 / 3he6 / 3he7 / 3huj / 3to4 / 4en3 / 6bnk / 6v7y / 6v7z
show 1 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Graft Versus Host Disease, Acute / Prevention of aGVHD1
1CompletedTreatmentPlasma Cell Myeloma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia (AML) / All / Blood Stem Cell Transplant Failure / Chemosensitive Hodgkin Lymphoma / CMML / Graft Versus Host Disease (GVHD) / Leukemia, Myelomonocytic, Chronic / Lymphoma, Hodgkins / MDS / MPN / Myelodysplastic Syndromes (MDS) / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
1WithdrawnTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHepatitis B Chronic Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000358 mg/mLALOGPS
logP8.69ALOGPS
logP12.67ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)12.16ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area168.94 Å2ChemAxon
Rotatable Bond Count44ChemAxon
Refractivity244.6 m3·mol-1ChemAxon
Polarizability110.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:41 / Updated on June 12, 2020 16:53